New report explores the liver diseases therapeutics market that is poised to grow at 15% CAGR to 2019

Print 12 October 2015
WhaTech

Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment.

The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early.

This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.

The complete Global Liver Diseases Therapeutics Market 2015-2019 Report is available at http://www.sandlerresearch.org/global-liver-diseases-therapeutics-market-2015-2019.html

Covered in this report

This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases.

Based on disease indication, the market is segmented as follows:

• Non-alcoholic fatty liver disease (includes non-alcoholic steatohepatitis)
• Liver cirrhosis
• Liver cancer
• Hepatitis (Hepatitis A, B, and C)

This report includes a discussion of the market in the following three regions:

• Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
• EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India.

Inquire on the Report at http://www.sandlerresearch.org/inquire-before-buying?rname=44187

The report, Global Liver Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the landscape of the global liver diseases therapeutics market and its growth prospects in the coming years.

The report includes a discussion of the key vendors operating in this market.

Key regions – America, EMEA and APAC

Key players – F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck

Other Prominent Vendors in the market are:Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, and Zafgen.

Source

Return